Pharma BD Deal Intelligence
A scale play with real upside: GSK handed CTTQ distribution across more than 5,000 medical centres in China for bepirovirsen, whose Phase 3 B-Well trials hit 19% functional cure rates in chronic hepatitis B, though the collaboration's financial terms were undisclosed.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK today announced positive headline results from the B-Well 1 and B-Well 2 phase III trials of bepirovirsen demonstrating statistically significant and…
CTTQ is set to handle importation, distribution, hospital access, and promotional activities while GSK retains the marketing authorization and responsibility…
The agreement grants GSK the ability to review certain early-stage pipeline assets of the SBP Group to evaluate the potential for collaboration opportunities…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK entered an exclusive strategic collaboration on May 11, 2026 with Sino Biopharmaceutical (SBP Group) via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) to accelerate the launch of bepirovirsen, a potential first-in-class antisense oligonucleotide for chronic hepatitis B (CHB), in mainland China. Under a supply-and-distribute structure, CTTQ purchases bepirovirsen from GSK under agreed supply terms and handles importation, distribution, hospital access (>5,000 medical centres) and promotional/non-promotional activities, while GSK remains the marketing authorisation holder and retains regulatory, quality, pharmacovigilance and global medical strategy responsibility; GSK is expected to book the sales of bepirovirsen supplied to CTTQ. The initial term is 5.5 years with mutual extension options. The agreement also grants GSK the right to review certain early-stage SBP Group pipeline assets to evaluate collaboration opportunities outside China. Financial terms were not disclosed. Bepirovirsen is under NMPA Priority Review in China and FDA Priority Review (Breakthrough Therapy Designation) in the US with an October 26, 2026 PDUFA target, supported by the Phase 3 B-Well 1/2 functional-cure readouts.
640K US cases/yr · $1.0B 2025 US hepatitis B treatment market · 19-26% Bepirovirsen B-Well functional cure rate (HBsAg <=3,000 / <=1,000 IU/mL strata)
Chronic hepatitis B (CHB) is a persistent infection with hepatitis B virus (HBV) that drives progressive liver injury, cirrhosis, and hepatocellular carcinoma, accounting for roughly 60% of global HCC cases. Standard-of-care nucleos(t)ide analogues (entecavir, tenofovir, TAF/Vemlidy) suppress HBV DNA but rarely achieve functional cure (HBsAg loss), forcing the vast majority of patients into lifelong therapy with ~1% annual rate of HBsAg clearance. Mainland China carries roughly one-third of the global CHB disease burden — an estimated 75 million people — while the CDC estimates approximately 640,000 US adults are living with chronic HBV (under-ascertained; community studies put true US prevalence closer to 1.6-2.4 million when foreign-born populations are included). Cure-oriented therapy is the central unmet need: even on indefinite nucleos(t)ide suppression, patients remain HBsAg-positive, require ongoing monitoring, carry meaningful HCC risk, and bear disease stigma. The 2026 Phase 3 readouts for bepirovirsen reframed expectations for finite-duration regimens, demonstrating functional cure rates of 19-26% in HBsAg-stratified subgroups versus 0% on placebo and validating antisense oligonucleotide knockdown of HBsAg as a clinically meaningful path to durable off-treatment response.
Nucleos(t)ide analogues (Gilead's Vemlidy/TAF, Viread/tenofovir, Bristol's Baraclude/entecavir) anchor the CHB market with potent HBV DNA suppression but ~1% annual functional cure, locking patients into lifelong therapy. Bepirovirsen positions as the first finite-duration functional-cure regimen with Phase 3 B-Well 1/2 demonstrating 19-26% HBsAg loss in low-baseline-HBsAg subgroups versus 0% placebo; FDA Priority Review accepted with an October 26, 2026 PDUFA target and NMPA Priority Review accepted in April 2026. China and the US together represent two-thirds of the addressable global market opportunity. GSK's tie-up with Sino Biopharm/CTTQ secures launch-day access to >5,000 Chinese medical centers and leverages CTTQ's category-leading hepatology footprint, while GSK retains marketing authorization and pricing. Pipeline competition (Vir's elebsiran/tobevibart siRNA + monoclonal combinations, Arrowhead/J&J JNJ-3989, Replicor's REP 2139) remains earlier-stage; bepirovirsen is positioned as the first-mover finite-cure entrant.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sino Biopharmaceutical Limited / GSK plc (this deal) | 2026 | — | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2026 deals · Infectious Disease deals